Pricing Log in Create free account
Friday 6 November 2026 Export MDGL’s income statement to Excel — free account

Madrigal Pharmaceuticals, Inc.

MDGL Healthcare Biotechnology

Madrigal Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $958.4 million, up 432.1% from fiscal 2024.

Revenue
+50.1%
EPS
+147.3%
Free cash flow
+53.5%
Total debt
+0.45%

Quarter to September 2026, against a year earlier

396.86 3.24 −0.81%
Market cap
$9.3B
P/E
0.0×
Fwd P/E
−68.8×
Dividend yield
—
F-score
n/a
Altman Z
10.48
Beneish M
0.50
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Madrigal Pharmaceuticals, Inc. (MDGL) Revenue

Alert me on Revenue

Madrigal Pharmaceuticals, Inc.'s revenue for fiscal 2025 was $958.4M, up 432.1% from $180.1M in fiscal 2024. Over the twelve months to 30 September 2026 it was $1.4B. Madrigal Pharmaceuticals, Inc. ranks 18th of 390 Biotechnology companies by revenue.

Revenue, annual

Embed this chart

Annual newest first

Period Revenue Change
FY2025 $958.4M 432.05%
FY2024 $180.1M —

Quarterly newest first

Period Revenue Change
Sep 2026 $431.3M 18.40%
Jun 2026 $364.3M 17.00%
Mar 2026 $311.3M (3.04%)
Dec 2025 $321.1M 11.77%
6 more quarters

Revenue against peers

Company Revenue
MDGL Madrigal Pharmaceuticals, Inc. $1.4B
CAI Caris Life Sciences,�Inc. compare $1.0B
TGTX TG Therapeutics, Inc. compare $799.5M
KRYS Krystal Biotech, Inc. compare $470.0M
TWST Twist Bioscience Corporation compare $431.8M
PTGX Protagonist Therapeutics, Inc. compare $282.0M
IBRX ImmunityBio, Inc. compare $165.8M
CYTK Cytokinetics, Incorporated compare $113.3M
SYRE Spyre Therapeutics, Inc. compare $1.1M

What Revenue is

Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.

Reported line item

The full definition of Revenue →

More on MDGL